Guide Disease Management of LRDs With ImmunoCAP®

What the profile will tell you

The ImmunoCAP® respiratory profile is designed to accomplish two tasks:

  1. To identify if a patient is allergic

  2. To identify the categories of allergens to which the patient is sensitized (ie, what his or her allergic “asthma triggers” may be)

The regional respiratory profiles contain not only the allergens usually found within a geographic region, but also those known to have cross-reactivity with other allergens.1 That is, if the profile for a specific area contains Bermuda grass, and the results are positive, the patient may be allergic to any of several grasses, because the allergic proteins for other local grasses can be similar enough to be recognized by the specific IgE for Bermuda grass.

Treatment considerations

For treatment at the primary care level, it is not so important to know which grass is causing the reaction, as it is whether grass is part of the problem.  While grass pollen may be difficult to avoid, knowing that grass pollen in general is a contributing factor may lead to pretreatment prior to grass pollen season, or dosage increases during that period.2  In addition, if other, more avoidable allergen sensitivities are identified, the elimination of any of them may impact the total allergic load.3,4

In the case of LRDs, symptomatic treatment is essential. However, mild or severe acute exacerbations of asthma may be triggered by allergen exposure.5  Understanding these sensitizations (triggers) can allow for avoidance measures and potentially mitigate the severity of, or even the exacerbations themselves.5,6

In the case of LRD, negative results indicate there is not an allergen basis for the disease; however, non-allergic triggers (smoke) may remain.

Positive results indicate atopy, with the quantitative results in kUA/L giving a suggestion of the major and minor contributors.  Although not all allergens produce the same level of response and not all immune systems react the same way, generally the quantitative scores reflect “severity of allergen impact.”

The management of positive patients becomes two pronged:

  1. With the knowledge provided in ImmunoCAP results, patients may be directed to undertake the environmental controls  Eliminating the major offending groups of allergens may have importance due to the “cumulative threshold response” of allergic disease.3,4

  2. Treat with allergy medications of choice; adjust dosage as necessary.5,6 Once daily dosing of oral second generation antihistamine offers a convenient and readily compliant treatment choice for truly allergic patients.